In general, PPARγ agonists inhibit tumor-associated angiogenesis by inhibiting FGF-2- and VEGF-induced EC growth, invasion and migration in vitro and in vivo [27, 192], downregulate expression of VEGF by tumor cells [195, 199] and VEGFRs by EC [32], and decrease tumor-associated MVD [24, 32, 198] and EC tube formation [202], measures of angiogenesis in vivo and in vitro, respectively. Here, PPARG is linked to neoplasm.